Our study adds to the current evidence base on the unmet need associated with anti-TNF therapies in China, where earlier recognition of treatment failures to allow timely alternative treatment decisions, revised reimbursement policies and/or new therapeutic options may improve long-term outcomes in patients with IBD. This evidence concerns the gene TNF and inflammatory bowel disease.